In addition, the lack of localization of 177Lu-DOTA-trastuzumab in negative HER-2 breast cancer patients indicates the specificity of this radiopharmaceutical for treatment of HER-2-positive breast cancer in the future.91 This evidence concerns the gene ERBB2 and breast cancer.